Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Tiberi

Showing results (71-80 of 147) with videos related to

Pageof 15
Sort By:
BMJ Open|July 10, 2021
Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort studyFrank Kloprogge, Ibrahim Abubakar, Hanif Esmail, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 2, 2020
Post tuberculosis treatment infectious complicationsDesmond Hsu, Muhammad Irfan, Kauser Jabeen, et al.
Expert Review of Anti-Infective Therapy|October 21, 2016
Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkersJan-Willem C Alffenaar, Onno W Akkerman, Richard M Anthony, et al.
Journal of Clinical Pharmacology|May 15, 2026
Randomized, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy AdultsEmma Ilsley, Edward Banham-Hall, Tetyana Chaychenko, et al.
The European Respiratory Journal|April 3, 2016
Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?Mathieu S Bolhuis, Simon Tiberi, Giovanni Sotgiu, et al.
The European Respiratory Journal|September 3, 2016
Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?Marlanka A Zuur, Onno W Akkerman, Lina Davies Forsman, et al.
The New Microbiologica|July 23, 2005
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavirNicola Gianotti, Elena Seminari, Monica Guffanti, et al.
Presse Medicale (Paris, France : 1983)|March 4, 2017
The cursed duet today: Tuberculosis and HIV-coinfectionSimon Tiberi, Anna Cristina C Carvalho, Giorgia Sulis, et al.
The European Respiratory Journal|June 27, 2020
On tuberculosis and COVID-19 co-infectionMarina Tadolini, José-María García-García, François-Xavier Blanc, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 15, 2018
Tuberculosis elimination: where are we now?Alberto Matteelli, Adrian Rendon, Simon Tiberi, et al.
Pageof 15

Showing results (71-80 of 147) with videos related to

Sort By:
Pageof 15
BMJ Open|July 10, 2021
Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort studyFrank Kloprogge, Ibrahim Abubakar, Hanif Esmail, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 2, 2020
Post tuberculosis treatment infectious complicationsDesmond Hsu, Muhammad Irfan, Kauser Jabeen, et al.
Expert Review of Anti-Infective Therapy|October 21, 2016
Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkersJan-Willem C Alffenaar, Onno W Akkerman, Richard M Anthony, et al.
Journal of Clinical Pharmacology|May 15, 2026
Randomized, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy AdultsEmma Ilsley, Edward Banham-Hall, Tetyana Chaychenko, et al.
The European Respiratory Journal|April 3, 2016
Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?Mathieu S Bolhuis, Simon Tiberi, Giovanni Sotgiu, et al.
The European Respiratory Journal|September 3, 2016
Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?Marlanka A Zuur, Onno W Akkerman, Lina Davies Forsman, et al.
The New Microbiologica|July 23, 2005
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavirNicola Gianotti, Elena Seminari, Monica Guffanti, et al.
Presse Medicale (Paris, France : 1983)|March 4, 2017
The cursed duet today: Tuberculosis and HIV-coinfectionSimon Tiberi, Anna Cristina C Carvalho, Giorgia Sulis, et al.
The European Respiratory Journal|June 27, 2020
On tuberculosis and COVID-19 co-infectionMarina Tadolini, José-María García-García, François-Xavier Blanc, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 15, 2018
Tuberculosis elimination: where are we now?Alberto Matteelli, Adrian Rendon, Simon Tiberi, et al.
Pageof 15